Therapeutic Targeting of RAS Mutant Cancers
Author(s): Edward C. Stites , Kendra Paskvan , Shumei Kato
Quantity
Pickup available at Cambridge University Press Bookshop
Usually ready in 24 hours
Therapeutic Targeting of RAS Mutant Cancers
Cambridge University Press Bookshop
1-2 Trinity Street
Cambridge CB2 1SZ
United Kingdom
🚚 Please note we can only ship within the UK.
FREE delivery on books (excluding sale).
Delivery for other items is £1.50 - £4.50, calculated at checkout.
T&Cs apply.
Free click & collect on all orders.
The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. This has led to the first FDA approval for a RAS targeted therapy. This new agent is a covalent inhibitor that reacts with the cysteine residue created by a codon 12 glycine to cysteine (G12C) mutation within KRAS. Mutant-specific strategies may also exist for other KRAS single nucleotide variants, and recent studies provide examples and mechanisms.
Choose options